Kyowa Kirin Launches New Efforts to Educate and Engage Physicians and Patients with Rare Forms of Cutaneous T-Cell Lymphoma About Treatment with POTELIGEO®

Kyowa Kirin, Inc., a global specialty pharmaceutical company, announced the launch of two efforts focused on increasing understanding of mycosis fungoides (MF) and Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL), and the role of POTELIGEO® (mogamulizumab-kpkc) in treating them.

Aimed at physicians, the new Treat the Blood. Treat the Skin. omni-channel campaign seeks to educate about the importance of measuring and monitoring blood involvement to inform treatment and potentially impact patient outcomes in MF and SS. To reach patients, POTELIGEO patient ambassadors will share their CTCL journeys and experiences on treatment through video testimonials and other educational programming. The launch of both initiatives coincides with Blood Cancer Awareness Month.

"To have a profound impact in a rare disease like CTCL, it's important to invest in education and programming that helps to advance disease awareness, recognition and management," said Sue Smith, Vice President, North American Oncology Franchise Head, Kyowa Kirin, Inc. "With increasing blood burden linked to poorer prognosis in both mycosis fungoides and Sézary syndrome, it's critical that the blood is monitored for disease progression and response to treatment. Our physician effort is focused on increasing understanding of the value of routine blood testing, and the proven efficacy of POTELIGEO in treating MF and SS symptoms."

For more information, go to https://www.poteligeo.com